Volume 61, Issue 3 pp. 146-151
Full Access

Toxic encephalopathy with hyperammonaemia during high-dose salicylate therapy

Anna-Liisa Mäkelä

Corresponding Author

Anna-Liisa Mäkelä

Department of Paediatrics and Clinical Neurophysiology, University of Turku, Turku, Finland

Dr. Anna-Liisa Mäkelä, Department of Paediatrics Turku University Hospital Kiinamyllynkatu 4–8 20520 Turku 52 FinlandSearch for more papers by this author
Heikki Lang

Heikki Lang

Department of Paediatrics and Clinical Neurophysiology, University of Turku, Turku, Finland

Search for more papers by this author
Paavo Korpela

Paavo Korpela

Department of Paediatrics and Clinical Neurophysiology, University of Turku, Turku, Finland

Search for more papers by this author
First published: March 1980
Citations: 25

Abstract

High-dose, long-term aspirin therapy easily overloads the patient's individual capacity to metabolize salicylates and may lead to complex metabolic disturbances including fulminant hepatic failure, hyperammonemia and toxic metabolic encephalopathy.

In the two cases presented there was a severe outbreak of hepatotoxic encephalopathy despite the fact that the dosage of salicylates did not exceed that generally recommended for children with rheumatic diseases. The justification of high-dose salicylate therapy is discussed, taking into account the fact that children with juvenile rheumatoid arthritis and allied conditions may have increased susceptibility to liver damage from drugs.

EEG abnormalities in these two cases corresponded to those described in other metabolic encephalopathies including Reye's syndrome. The quality of the EEG changes gives prognostic signs, but is of restricted value in establishing the etiology without the anamnestic data of salicylate ingestion. Active therapeutic measures including exchange transfusions are needed to prevent irreversible metabolic and pressure changes in the brain.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.